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In mid-June, the World Health Organization (WHO) recognized the Lambda variant as
a so-called Variants of Interest (VOI) [1]. In addition to Lambda, this list includes six others: 
Epsilon (B.1.427/B.1.429, formerly Californian), Iota (B.1.526, New York), and Theta (P.3, 
Filipino). This means that these variants have mutations that affect, inter alia, the ease of 
transmission of the pathogen, the severity of the disease, the ability to avoid vaccines, or 
misleading diagnostic tests. On the basis of genome sequencing, it was estimated that this 
variant contains 27 mutations (1 in ORF1a — deletion 3675-3677; 7 in the gene encoding 
protein S — deletion 246-252, G75V, T76I, L452Q, F490S, D614G and T859N as well as 19 
other mutations which are observed in various known variants of the SARS-2 coronavirus). 
Among the Lambda variant mutations, the L452Q mutation was identified, which is similar to
the L452R mutation observed in the Delta and Epsilon variants [2]. A new variant of interest 
in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), designated Lambda, has 
spread in recent months in some South American countries, but its virological and 
evolutionary features remain unknown. The Lambda variant spike protein may increase viral 
infectivity, which is attributed to the mutations designated T76I and L452Q. The 
RSYLTPGD246-253N mutation, which is a unique 7-amino acid deletion in the N-terminal 
domain of the Lambda variant spike protein, avoids neutralizing antibodies. As the SARS-
CoV-2 Lambda variant has spread dominantly in line with the increasing frequency of isolates
carrying the RSYLTPGD246-253N mutation, these data suggest that the insertion of the 
RSYLTPGD246-253N mutation is closely related to the massive spread of Lambda variant 
infection in South America. Thus, the spike protein of the Lambda variant increases its 
infectivity, and the T76I and L452Q mutations are responsible for this property, and together 
with the RSYLTPGD246-253N and F490S mutation they confer resistance to antiviral 
antibodies [3]. The effect of such mutations on infectivity and immune escape from 
neutralizing antibodies is completely unknown to us. The studies showed an increased 
infectivity of the Lambda variant, which was even higher than that of D614G (a line of alpha 
and gamma variants). Compared to the wild type (line A), the neutralization was reduced 
3.05-fold for the Lambda variant, while it was 2.33-fold for the Gamma variant and 2.03-fold 
for the Alpha variant. These results indicate that mutations present in the spike protein of the 
Lambda variant of interest result in increased infectivity and immune escape from 
neutralizing antibodies induced by an inactivated CoronaVac vaccine (not available in the 
European Union or the United States). These results show that in countries with high levels of
SARS-CoV-2 virus infections, genetic surveillance should be associated with the 
identification of new isolates harboring mutations in the spike protein gene and 
immunological studies to determine the effect of these mutations on immune escape and 
breaking vaccine immunity [4]. Fortunately, the lambda variant remains susceptible to 
neutralization by vaccine-induced mRNA antibodies. Lambda variant was more infectious and
was neutralized by convalescent sera and vaccine-induced antibodies with a relatively small 
2.3–3.3-fold decrease in titer, however this decrease was present. therefore, vaccination based 
on mRNA technology should be used universally and the whole world should focus on their 
universal use as well as on enabling their use in poorer countries [5]. According to Johns 
Hopkins Coronavirus Resource Center, Peru currently has the highest mortality rate, which is 
600 deaths per 100,000 infected with COVID-19, in addition, the WHO reports that in Peru, 
the lambda varianthas affected about 81% of patients since April, which additionally raises 
concern about the spread of this variant around the world [6].
We must pay special attention to the lambda variant of the SARS-CoV-2 virus due to 
its possible escape from the surveillance of the host’s immune response and possible 
ineffectiveness or limited effectiveness of preventive vaccinations. We should also consider a 
possible change in vaccination in countries such as Peru and the use of the most effective of 
them, such as those produced by Pfizer and Moderna, based on mRNA technology. 
Vaccinating the society as quickly as possible and with the most effective preparations should 
reduce the transmission of the virus and the risk of mutations that will no longer be resistant 
to the preventive measures we currently know. In the case of the lambda variant, it is also 
necessary to consider the introduction of compulsory wearing of masks and travel restrictions,
as well as implementing quarantine for returnees, regardless of vaccination status.
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